Investors want Recell to hit earnings guidance for the year. There's a high chance that Avita won't hit it. That would equal another guidance revision and another 40% drop in SP. After a couple of guidance failures with earnings and another guidance failure with Recell Go in September, investors are tired of the crap. It's debatable that the SP could go down AFTER Go approval if the guidance isn't met.
Ann: AVITA Medical to Announce First Quarter 2024 Results, page-151
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.50 |
Change
-0.030(1.19%) |
Mkt cap ! $169.5M | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.51 | $2.45 | $380.9K | 153.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $2.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.51 | 688 | 2 |
View Market Depth
| Last trade - 14.57pm 10/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |